切换至 "中华医学电子期刊资源库"

中华移植杂志(电子版) ›› 2024, Vol. 18 ›› Issue (02) : 86 -92. doi: 10.3877/cma.j.issn.1674-3903.2024.02.003

专家论坛

实体器官移植后难治性/耐药性巨细胞病毒感染诊疗进展
巨春蓉1, 门同义2, 薛武军3,()   
  1. 1. 510120 广州医科大学附属第一医院 广州呼吸健康研究院呼吸疾病国家重点实验室 国家呼吸疾病临床医学研究中心
    2. 呼和浩特 750306,内蒙古医科大学附属医院泌尿外科
    3. 710061 西安交通大学附属第一医院肾移植科
  • 收稿日期:2024-02-04 出版日期:2024-04-25
  • 通信作者: 薛武军
  • 基金资助:
    呼吸疾病国家重点实验室/广州呼吸健康研究院/国家呼吸中心临床自主探索项目(SKLRHQN20205); 广东省钟南山医学基金会(ZNSA-2020013); 广东省自然科学基金(2022A1515012216); 广州市临床特色技术项目(2023C—TS10); 广州医科大学科研能力提升计划重大临床研究项目(GMUCR2024-01007)

Progression in diagnosis and treatment of refractory/resistant cytomegalovirus infection after solid organ transplantation

Chunrong Ju1, Tongyi Men2, Wujun Xue3,()   

  1. 1. The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, National Key Laboratory of Respiratory Disease, National Clinical Medical Research Center of Respiratory Disease, Guangzhou 510120, China
    2. Department of Urinary Surgery, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot 750306, China
    3. Department of Kidney Transplantation, the First Affiliated Hospital of Xi′an Jiaotong University, Xi′an 710061, China
  • Received:2024-02-04 Published:2024-04-25
  • Corresponding author: Wujun Xue
引用本文:

巨春蓉, 门同义, 薛武军. 实体器官移植后难治性/耐药性巨细胞病毒感染诊疗进展[J/OL]. 中华移植杂志(电子版), 2024, 18(02): 86-92.

Chunrong Ju, Tongyi Men, Wujun Xue. Progression in diagnosis and treatment of refractory/resistant cytomegalovirus infection after solid organ transplantation[J/OL]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(02): 86-92.

随着我国实体器官移植(SOT)事业的飞速发展,巨细胞病毒(CMV)感染的发病人数日益增多。其中,耐药性和难治性CMV感染的发病率也逐渐升高,导致SOT受者的死亡率显著增加,值得临床高度关注。随着新的诊断技术出现和新药的研发上市,难治性/耐药性CMV感染的诊疗不断发展。本文总结了SOT受者难治性CMV感染的诊治新进展,包括难治性/耐药性CMV感染的定义、诊断以及治疗策略,旨在为预防和治疗SOT后难治性/耐药性CMV感染提供参考。

With the rapid development of solid organ transplantation (SOT) in China, the number of people infected with cytomegalovirus (CMV) is increasing. The incidence rate of resistant CMV and refractory CMV infection is also increasing, leads to the mortality increase significantly, which require clinical attention. Along with improvement of the new diagnostic technologies and new drugs, the diagnosis and treatment of refractory/resistant CMV infection continue to improve. This review summarizes the new progress in the diagnosis and treatment strategies on refractory CMV infection in SOT recipients, including the definition, the diagnosis and treatment strategies. The article is aimed to provide references for prevention and treatment of refractory/drug resistant CMV infection in organ transplant recipients.

图1 目前临床对实体器官移植受者耐药性CMV感染的诊治流程注:GCV.更昔洛韦;VGCV.缬更昔洛韦;FOS.膦甲酸钠;EC 50.半数有效浓度;CDV.西多福韦
1
Kotton CN. CMV: Prevention, diagnosis and therapy[J]. Am J Transplant, 2013, 13 Suppl 3:24-40.
2
Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation[J]. JAMA, 1989, 261(24):3607-3609.
3
巨春蓉,练巧燕,蔡宇航,等. 胸腔脏器移植受者巨细胞病毒感染情况及预后分析[J/CD]. 中华移植杂志:电子版2021, 15(4):193-198.
4
巨春蓉,郝建清,何建行,等. 移植受者耐药巨细胞病毒感染的诊治[J]. 中华器官移植杂志2023, 44(3):146-151.
5
巨春蓉,韦兵,练巧燕,等. 实体器官移植术后巨细胞病毒肺炎的防治策略—ATS巨细胞病毒肺炎的诊治指南解读[J]. 器官移植2019, 10(1):88-90.
6
Yong MK, Shigle TL, Kim YJ, et al. American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation[J]. Transplant Cell Ther, 2021, 27(12):957-967.
7
Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation[J]. Transplantation, 2018, 102(6):900-931.
8
Humar A, Siegal D, Moussa G, et al. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients[J]. J Infect Dis, 2005, 192(7):1154-1157.
9
Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients[J]. Am J Transplant, 2007, 7(9):2106-2113.
10
Fisher CE, Knudsen JL, Lease ED, et al. Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients[J]. Clin Infect Dis, 2017, 65(1):57-63.
11
Hofmann E, Sidler D, Dahdal S, et al. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: a case series and review of the literature[J]. Transpl Infect Dis, 2021, 23(3):e13515.
12
Van Leer Buter CC, de Voogd DWK, Blokzijl H, et al. Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands[J]. J Antimicrob Chemother, 2019, 74(8):2370-2376.
13
Brar S, Berry R, Raval AD, et al. Outcomes among CMV-mismatched and highly sensitized kidney transplants recipients who develop neutropenia[J]. Clin Transplant, 2022, 36(4):e14583.
14
Kotton CN, Kamar N. New insights on CMV management in solid organ transplant patients: prevention, treatment, and management of resistant/refractory disease[J]. Infect Dis Ther, 2023, 12(2):333-342.
15
Khawaja F, Spallone A, Kotton CN, et al. Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium[J]. Clin Microbiol Infect, 2023, 29(1):44-50.
16
Ju C, Wang X, Xu X, et al. Cytomegalovirus seroprevalence, infection, and disease in Chinese thoracic organ transplant recipients: a retrospective cohort study[J]. BMC Infect Dis, 2022, 22(1):872.
17
Boivin G, Goyette N, Rollag H, et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir[J]. Antivir Ther, 2009, 14(5):697-704.
18
Lurain NS, Bhorade SM, Pursell KJ, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients[J]. J Infect Dis, 2002, 186(6):760-768.
19
Ambrose T, Sharkey LM, Louis-Auguste J, et al. Cytomegalovirus infection and rates of antiviral resistance following intestinal and multivisceral transplantation[J]. Transplant Proc, 2016, 48(2):492-496.
20
Limaye AP, Babu TM, Boeckh M. Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation[J]. Clin Microbiol Rev, 2020, 34(1):e00043-19.
21
Linares L, Sanclemente G, Cervera C, et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients[J]. Transplant Proc, 2011, 43(6):2145-2148.
22
Al-Badr AA, Ajarim TDS. Ganciclovir[J]. Profiles Drug Subst Excip Relat Methodol, 2018, 43:1-208.
23
El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients[J]. Blood, 2016, 128(23):2624-2636.
24
Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus[J]. Clin Microbiol Rev, 2010, 23(4):689-712.
25
Kleiboeker SB. Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients[J]. Antiviral Res, 2023, 215:105623.
26
Jabs DA, Enger C, Forman M, et al. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group[J]. Antimicrob Agents Chemother, 1998, 42(9):2240-2244.
27
Görzer I, Guelly C, Trajanoski S, et al. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time[J]. J Virol, 2010, 84(14):7195-7203.
28
Sahoo MK, Lefterova MI, Yamamoto F, et al. Detection of cytomegalovirus drug resistance mutations by next-generation sequencing[J]. J Clin Microbiol, 2013, 51(11):3700-3710.
29
Chou S, Ercolani RJ, Sahoo MK, et al. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing[J]. Antimicrob Agents Chemother, 2014, 58(8):4697-4702.
30
Chou S. Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance[J]. Antiviral Res, 2020, 176:104711.
31
Mallat SG, Tanios BY, Itani HS, et al. CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials[J]. Clin J Am Soc Nephrol, 2017, 12(8):1321-1336.
32
Zafrani L, Truffaut L, Kreis H, et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study[J]. Am J Transplant, 2009, 9(8):1816-1825.
33
Hayes M, Boge CLK, Sharova A, et al. Antiviral toxicities in pediatric solid organ transplant recipients[J]. Am J Transplant, 2022, 22(12):3012-3020.
34
Avery RK, Arav-Boger R, Marr KA, et al. Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection[J]. Transplantation, 2016, 100(10):e74-e80.
35
Mehta Steinke SA, Alfares M, Valsamakis A, et al. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection[J]. Transpl Infect Dis, 2021, 23(3):e13521.
36
Koszalka GW, Johnson NW, Good SS, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication[J]. Antimicrob Agents Chemother, 2002, 46(8):2373-2380.
37
Wang LH, Peck RW, Yin Y, et al. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects[J]. Antimicrob Agents Chemother, 2003, 47(4):1334-1342.
38
Papanicolaou GA, Silveira FP, Langston AA, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, Phase 2 study[J]. Clin Infect Dis, 2019, 68(8):1255-1264.
39
Maertens J, Cordonnier C, Jaksch P, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation[J]. N Engl J Med, 2019, 381(12):1136-1147.
40
Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a Phase 3 randomized clinical trial[J]. Clin Infect Dis, 2022, 75(4):690-701.
41
Bassel M, Romanus D, Bo T, et al. Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: data at 52 weeks post-maribavir treatment initiation[J]. Antivir Ther, 2023, 28(5):13596535231195431.
42
Strasfeld L, Lee I, Tatarowicz W, et al. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir[J]. J Infect Dis, 2010, 202(1):104-108.
43
Chou S, Marousek GI. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain Ⅱ mutant[J]. J Virol, 2008, 82(1):246-253.
44
Sassine J, Khawaja F, Shigle TL, et al. Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era[J]. Clin Infect Dis, 2021, 73(8):1346-1354.
45
Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246[J]. Am J Transplant, 2011, 11(5):1079-1084.
46
Phoompoung P, Ferreira VH, Tikkanen J, et al. Letermovir as salvage therapy for cytomegalovirus infection in transplant recipients[J]. Transplantation, 2020, 104(2):404-409.
47
Turner N, Strand A, Grewal DS, et al. Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis[J]. Antimicrob Agents Chemother, 2019, 63(3):e02337-18.
48
Alvarez-Cardona JJ, Whited LK, Chemaly RF. Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections[J]. Future Microbiol, 2020, 15:389-400.
49
Marty FM, Winston DJ, Chemaly RF, et al. A randomized, double-blind, placebo-controlled Phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(2):369-381.
50
Vial R, Zandotti C, Alain S, et al. Brincidofovir use after foscarnet crystal nephropathy in a kidney transplant recipient with multiresistant cytomegalovirus infection[J]. Case Rep Transplant, 2017:3624146.
51
Alexander BT, Hladnik LM, Augustin KM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients[J]. Pharmacotherapy, 2010, 30(6):554-561.
52
Wiening V, Schmidt T, Dahmen M, et al. Case report: management of a multidrug-resistant CMV-strain in a renal transplant recipient by high-dose CMV-specific immunoglobulins, modulation in immunosuppression, and induction of CMV-specific cellular immunity[J]. Front Immunol, 2020, 11:623178.
53
Pearston AP, Ingemi AI, Ripley K, et al. Successful treatment of UL97 mutation ganciclovir-resistant cytomegalovirus viremia in a renal transplant recipient with letermovir and adjunct hyperimmune cytomegalovirus immunoglobulin: a case report[J]. Transplant Proc, 2021, 53(4):1284-1287.
54
Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis[J]. J Clin Oncol, 2009, 27(5):770-781.
55
Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones[J]. Science, 1992, 257(5067):238-241.
56
Ke P, Bao X, Zhou J, et al. Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation[J]. Hematology, 2020, 25(1):43-47.
57
Smith C, Beagley L, Rehan S, et al. Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label Phase I clinical trial[J]. Clin Infect Dis, 2019, 68(4):632-640.
58
Holmes-Liew CL, Holmes M, Beagley L, et al. Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation[J]. Clin Transl Immunology, 2015, 4(3):e35.
59
Miele M, Gallo A, Di Bella M, et al. Successful use of heterologous CMV-reactive T lymphocyte to treat severe refractory cytomegalovirus (CMV) infection in a liver transplanted patient: correlation of the host antiviral immune reconstitution with CMV viral load and CMV miRNome[J]. Microorganisms, 2021, 9(4):684.
60
Macesic N, Langsford D, Nicholls K, et al. Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient[J]. Am J Transplant, 2015, 15(3):827-832.
[1] 涂家金, 廖武强, 刘金晶, 涂志鹏, 毛远桂. 严重烧伤患者鲍曼不动杆菌血流感染的危险因素及预后分析[J/OL]. 中华损伤与修复杂志(电子版), 2023, 18(06): 491-497.
[2] 郑宝英, 黄小兰, 贾楠, 朱春梅. 儿童难治性肺炎支原体肺炎早期预警指标[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(04): 215-221.
[3] 袁柳凤, 徐文绮, 朱小宇, 王慧珠, 伦文辉. 283株淋球菌对七种常见抗菌药物的耐药性分析[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(02): 108-112.
[4] 韦涌涛, 王松霞, 苏爱美, 王东平. 耐碳青霉烯类铜绿假单胞菌耐药性及联合药敏试验研究[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(01): 43-48.
[5] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[6] 巨春蓉, 孙启全, 薛武军. 器官移植受者非结核分枝杆菌病诊疗进展[J/OL]. 中华移植杂志(电子版), 2024, 18(01): 1-6.
[7] 邢嘉翌, 龚佳晟, 祝佳佳, 陆群. 肺癌化疗患者继发肺部感染的病原菌耐药性及炎症因子变化分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 714-718.
[8] 杨慧, 郭丽娟, 冯晓丹, 李静, 黄成谋, 蔡兴锐, 覃英娇, 王远礼. 非小细胞肺癌铂类药物耐药mi RNA表达特征及预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 719-724.
[9] 王蕊, 林先萍, 李盼盼. 铜绿假单胞菌感染肺炎菌血症危险因素及耐药性分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(03): 478-480.
[10] 蔡小芳, 高慧, 葛军, 邢慧芸, 庄小燕, 李小丁. 多重耐药性肺结核治疗依从性预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(01): 51-56.
[11] 张小凤, 孙晓琴, 黄军, 冀涵页, 杨辉, 侯智, 张春青. 标准前颞叶切除术治疗药物难治性癫痫[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(03): 189-192.
[12] 孙晓琴, 刘仕勇, 石先俊, 安宁, 杨辉, 张春青. 环岛叶大脑半球离断术治疗药物难治性癫痫[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(02): 126-128.
[13] 朱洪申, 王思权, 彭靓, 张晓斌, 郑美云, 陈锦华. Glubran-2栓塞治疗鼻咽癌相关难治性鼻出血的临床疗效[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 333-337.
[14] 崔伟, 叶苏意, 邓屹, 陈晓明, 张靖, 李静, 许荣德. 载药微球支气管动脉化疗栓塞术治疗难治性非小细胞肺癌的临床疗效及安全性[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 311-316.
[15] 詹维强, 李梦蝶, 涂玉玲, 郭艳, 芦乙滨, 史新格, 许明. 早期CRRT联合VA-ECMO治疗难治性心源性休克的临床效果[J/OL]. 中华卫生应急电子杂志, 2024, 10(05): 260-268.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?